George Health – Governance and Management
Total Page:16
File Type:pdf, Size:1020Kb
George Health – Governance and Management. An Australian Company providing innovative global treatment solutions for common serious chronic diseases George Health Enterprises – Board of Directors Dr Srinivas Akkaraju Yasmin Allen Chairman Director Srinivas Akkaraju is a former General Yasmin Allen is a Non-Executive Director Partner of Sofi nnova Ventures. Prior of Cochlear Limited, Chairman of its to Sofi nnova, Srinivas was a Managing Audit Committee and a Member of Director of New Leaf Venture Partners, Cochlear’s Technology Committee. She and prior to that, a Founding Managing is also a Non-Executive Director of ASX Director at Panorama Capital, LLC. Prior to that, Srinivas Limited and a Member of the ASX Audit Committee was a Partner with J.P. Morgan Partners. Srinivas currently and ASX Clearing and Settlement Board. Yasmin is a serves as a Director of Intercept Pharmaceuticals Inc, Director at Santos Limited and a Member of Santos’ Seattle Genetics, Versartis Inc, and aTyr Pharma Inc. Remuneration Committee and Environment, Health and Previously, Srinivas served as a Director on the boards of Safety Committee. She is also a Director of the National ZS Pharma Inc, Eyetech Pharmaceuticals Inc, Synageva Portrait Gallery. She is a Fellow of the Australian Institute Biopharma Corp, Barrier Therapeutics Inc, and Amarin of Company Directors. Yasmin joined the Board in August Corporation plc. Srinivas joined the Board in February 2014. 2016. Scott Featherston Professor Stephen MacMahon Director Principal Director & founder of TGI Scott is the Managing Partner at Caerus Co-founder of The George Institute for Capital, a private investment fi rm that Global Health; Professor of Medicine focuses on the health and education and James Martin Professorial Fellow, sectors in emerging markets. Scott was University of Oxford; Professor of formerly the Global Health Sector Leader Cardiovascular Medicine & Epidemiology, and a Principal Investment Offi cer for the International the University of Sydney; Honorary Professor, Peking Finance Corporation, the private sector arm of the World University Health Science Center; Honorary Consultant, Bank Group. During his time at IFC (2005-2015), Scott Royal Prince Alfred Hospital (Sydney); Fellow of the led numerous transactions in the health and education Australian Academy of Sciences, the British Academy of sectors in Africa, MENA, South/East Asia, and Europe and Medical Science and the American College of Cardiology founded the World Bank’s Health in Africa initiative. Scott’s and EY Social Entrepreneur of the Year. Stephen was early career was in engineering and fi nance. He worked previously Chairman of the Scientifi c Board of the UK for a global property and project management fi rm before Biobank, Chairman of the World Bank-GIHR Initiative for joining the fi nance advisory practice of a “Big 4” global Cardiovascular Health and Executive Chairman of George consulting fi rm. Clinical Pty Ltd. Stephen has been a director of the Board since is establishment in 1999. Dr Mohit Kaushal Director Staph Leavenworth Bakali Dr. Kaushal has had an extensive career President & CEO, Director within investing, clinical medicine, Staph has 28 years of considerable senior academia, and public policy. Mohit is executive and board level experience a lead investor and board member to in leading large complex and start numerous transformational companies up organisations in both developed including Humedica (acquired by Optum Health), and emerging markets in the global Rxante (acquired by Millennium), Change Healthcare pharmaceutical, biotechnology and not-for profi t health (acquired by Emdeon). During his time in the Obama arenas. Staph has substantial experience and a proven administration, he was a member of the White House track record in negotiating and concluding a wide range Health IT task force; a cross agency team implementing of public and private sector agreements and partnerships, the technology aspects of the ACA and testifi ed to including cross border mergers and acquisitions. Staph Congress on the application of benefi cial technology previously was President & Chief Operating Offi cer of the and payment reform to the Medicare population.He also Clinton Health Access Initiative (CHAI). Prior to CHAI, he built and led the fi rst daedicated health care team at the held several senior executive and Board positions with Federal Communications Commissio. In addition, his leading pharmaceutical and biotechnology companies. team reformed the Rural Healthcare fund to create the Staph holds a Masters in Management from London Healthcare Connect Fund, which aligned the funding Business School. mechanism with wider health care payment. George Health Enterprises 2 2017 Governance George Health Enterprises – Executive Team Staph Leavenworth Bakali Professor Stephen MacMahon President & CEO, Director Principal Director & founder of TGI Staph has 28 years of considerable senior Co-founder of The George Institute for executive and board level experience Global Health; Professor of Medicine in leading large complex and start and James Martin Professorial Fellow, up organisations in both developed University of Oxford; Professor of and emerging markets in the global Cardiovascular Medicine & Epidemiology, pharmaceutical, biotechnology and not-for profi t health the University of Sydney; Honorary Professor, Peking arenas. Staph has substantial experience and a proven University Health Science Center; Honorary Consultant, track record in negotiating and concluding a wide range Royal Prince Alfred Hospital (Sydney); Fellow of the of public and private sector agreements and partnerships, Australian Academy of Sciences, the British Academy of including cross border mergers and acquisitions. Staph Medical Science and the American College of Cardiology previously was President & Chief Operating Offi cer of the and EY Social Entrepreneur of the Year. Stephen was Clinton Health Access Initiative (CHAI). Prior to CHAI, he previously Chairman of the Scientifi c Board of the UK held several senior executive and Board positions with Biobank, Chairman of the World Bank-GIHR Initiative for leading pharmaceutical and biotechnology companies. Cardiovascular Health and Executive Chairman of George Staph holds a Masters in Management from London Clinical Pty Ltd. Stephen has been a director of the Board Business School. since is establishment in 1999. Dr Eliot Charles Glenn Kerkhof CEO George Medicines Executive Chairman George Clinical Dr Charles has previously been a Venture Glenn is Executive Chairman of George Partner at New Leaf Venture Partners, and of Clinical. Glenn has over 22 years’ a Partner at Apax Partners, Inc., a global experience in the contract research or private equity fi rm. Previous positions in drug development industry and joined the biopharmaceutical industry include George Clinical from Chiltern where COO at Principia Biopharma, Head, External R&D he was Chief Executive Offi cer. Prior to Chiltern, Glenn Aff airs at Amgen, and Director, Business Development served as Vice President, Clinical Services for Charles River at Genentech, Inc. He holds a Ph.D. in Neuroscience from Laboratories and as Vice President, Clinical Europe for the Massachusetts Institute of Technology and an M.B.A. Inveresk Research. In addition, he is also non-executive from the University of Chicago. director of Cell Care Australia Pty. Ltd. and Immunoglobal Pty. Ltd. He holds a Bachelor of Commerce from Professor Anushka Patel Deakin University (Australia) and a Masters of Business CEO George Care Administration from the University of Edinburgh (UK). Anushka is a Professor of Medicine at The University of Sydney and a cardiologist Tim Regan at Royal Prince Alfred Hospital in Sydney, Chief Operating Offi cer Australia. She undertook her medical Chief Financial Offi cer training at the University of Queensland, Director and former President of the with subsequent postgraduate research degrees from Financial Executives Institute in Australia; Harvard University and the University of Sydney. As the former Director of Thomas & Coff ey; Chief Scientist of the George Institute for Global Health, Bachelor of Economics, the University she has a key role in developing and supporting global of Sydney; Fellow of the Australian Institute of Company strategic initiatives across the organisation, especially with Directors, Institute of Chartered Accountants and international collaborators. Her personal research interests Australian Property Institute. Prior experience includes focus on developing innovative solutions for delivering former COO of Mirvac Group; CEO of TJS Services; aff ordable and eff ective chronic disease care in the Commercial Manager for Sydney Organising Committee community and in acute care hospital settings. Anushka for the Olympic Games; and Senior Manager at currently leads research projects relating to these interests PricewaterhouseCoopers. in Australia, Europe, China and India. George Health Enterprises 3 2017 Governance The George Insitute for Global Health – Board of Directors Michael Hawker AM Yasmin Allen Chairman Yasmin Allen is a Non-Executive Director Michael Hawker is a Non-Executive of Cochlear Limited, Chairman of its Director of Aviva Plc Group (UK), the Audit Committee and a Member of Macquarie Group Limited, Macquarie Cochlear’s Technology Committee. She Bank Limited and Washington H. Soul is also a Non-Executive Director of ASX Pattinson. Michael is Chair of the Australian Limited and a Member of the ASX Audit Business